长链非编码RNA在气道炎症性疾病中的作用  

Roles of lncRNA in airway inflammatory diseases

作　　者：陈祝 梁海海[1] CHEN Zhu;LIANG Haihai(College of Pharmacy,Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学药学院,哈尔滨150081

出　　处：《生命的化学》2024年第3期397-403,共7页Chemistry of Life

基　　金：黑龙江省杰出青年基金资助项目(JQ2022H001)。

摘　　要：气道炎症性疾病是以异常增强的气道炎症、气道阻塞和气道重塑为特征的疾病,主要包括哮喘和慢性阻塞性肺病等。近年来,气道炎症性疾病的发病率逐年上升,给全球医疗卫生事业造成巨大负担,然而其发病机制尚未完全阐明,亟需寻找治疗气道炎症性疾病的分子靶点。长链非编码RNA(long non-coding RNA,lncRNA)在气道炎症性疾病中表达失调,充当关键的调控分子,影响气道炎症性疾病的发生与进展。异常表达的lncRNA有望成为气道炎症性疾病的生物标志物和治疗靶点。本文就lncRNA在气道炎症性疾病中的作用进行综述。Airway inflammatory diseases are characterized by abnormally enhanced airway inflammation,airway obstruction,and airway remodeling,mainly including asthma and chronic obstructive pulmonary disease.The incidence of airway inflammatory diseases is rising steadily in recent years,placing a huge burden on the global healthcare.However,its pathogenesis has not been fully clarified,and it is urgent to find molecular targets for the therapy of airway inflammatory diseases.Long non-coding RNA(lncRNA)is dysregulated in airway inflammatory diseases,acting as a key regulatory molecule that affects the occurrence and progress of airway inflammatory diseases.Abnormally expressed lncRNA is expected to be a biomarker and therapeutic target for airway inflammatory diseases.This paper reviews the roles of lncRNA in airway inflammatory diseases.

关 键 词：长链非编码RNA 气道炎症性疾病 生物标志物 治疗靶点 

分 类 号：R56[医药卫生—呼吸系统]